BioBridgeX
Log inCompare quotes
Modality

Combination Product / Device CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Outsourcing a combination product (drug plus device, like an autoinjector, prefilled syringe, inhaler, or on-body delivery system) means coordinating pharma CMC with medical-device engineering. Buyers source CRO and CDMO partners for device design and design controls, human factors and usability testing, drug-device integration, container-closure and extractables/leachables work, fill-finish, and 21 CFR Part 4 regulatory support. On BioBridgeX, the neutral vendor of record, buyers compare qualified vendors free, under one contract.

Combination Product / Device CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Combination Product / Device CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Combination Product / Device drug?

A combination product lives in two regulatory worlds at once. You have a drug or biologic that has to behave like a drug (stability, potency, sterility, the full CMC package), and you have a device that has to behave like a device (design controls, mechanical reliability, biocompatibility, usability). An autoinjector, a prefilled syringe, a dry-powder inhaler, an on-body injector, a transdermal patch, a drug-eluting stent: each pairs a molecule with a delivery system, and the FDA assigns a primary mode of action (PMOA) that decides which center leads the review and which framework dominates. Getting the PMOA call right early shapes everything downstream, because it determines whether you are running a drug program with device elements bolted on or a device program with a drug inside.

The work that trips up first-time combination-product sponsors is rarely the molecule. It is the integration. The drug and the device interact, and you have to prove they play well together. Extractables and leachables from the device materials can contaminate the drug; the drug formulation can degrade an elastomer seal or corrode a needle; the device has to deliver the right dose, every time, across the product's shelf life and across the temperatures it will see in a patient's bag. That means container-closure integrity work, material compatibility studies, functional and dose-accuracy testing on the assembled product, and stability run on the finished combination, not just the drug substance. None of it is optional, and most of it cannot start until the device design is reasonably locked.

Two regulatory pillars sit underneath all of it. Design controls under 21 CFR 820.30 (and the ISO 13485 quality system the device side runs on) require a documented chain from user needs to design inputs, outputs, verification, validation, and a design history file. Human factors and usability engineering, covered by IEC 62366 and the FDA's human-factors guidance, requires that you study real users handling the device and run a validation study showing they can use it safely without critical use errors. A self-injecting patient who misreads the device is a safety signal, and the agency will ask for the data. 21 CFR Part 4 is the rule that ties the drug GMP and the device quality system together into one coherent set of obligations.

This is exactly where specialist combination-product CDMOs separate from generalists. A pure fill-finish CDMO can fill your prefilled syringe; it usually cannot run device design controls, build a usability lab, or own the design history file. A pure contract device manufacturer can mold and assemble an autoinjector; it often does not hold the drug GMP, sterility assurance, or CMC depth your molecule needs. The strongest partners do both under one roof, or you assemble a device-development house, a drug fill-finish site, and a human-factors CRO and make them work to one integrated plan. Whichever route you pick, someone has to own the seams between them, because the FDA reviews the product as one thing.

How do you choose a CRO or CDMO for Combination Product / Device?

The selection problem here is harder than for a single-modality program, because you are scoring two competencies and the bridge between them. A vendor that is brilliant at injectable fill-finish but treats the device as an afterthought will leave you holding the design controls and human-factors risk. A vendor that is a strong device shop but light on aseptic processing puts your sterility assurance at risk. Score candidates against the same written scope, and weight the integration capability heavily, not just the headline manufacturing rate.

Work through the checklist below before you sign anything.

  • Relevant platform and track record: ask for finished combination products in your delivery format (autoinjector, prefilled syringe, pen, inhaler, on-body injector, transdermal, drug-eluting device) and your route, not generic device or generic fill-finish experience. A team that has shipped your exact format has already solved problems you have not seen yet.
  • Drug-device integration depth: confirm they can run material compatibility, extractables and leachables, container-closure integrity, dose-accuracy and functional testing on the assembled product, and stability on the finished combination, not only on the drug substance. This is the work that fails late and expensively if it is skipped early.
  • Design controls and quality systems: verify a working design controls process under 21 CFR 820.30, an ISO 13485 quality system on the device side, and the drug GMP on the pharma side, governed together under 21 CFR Part 4. Ask who owns the design history file and where it lives.
  • Human factors and usability capability: check for in-house or partnered human-factors engineering, formative studies, and the ability to run a validation usability study to IEC 62366 and FDA human-factors guidance. For a self-administered product this is a gating deliverable, not a nice-to-have.
  • Analytical and GxP capability for this modality: confirm the analytical methods for your finished product, biocompatibility testing per ISO 10993, sterility assurance and aseptic fill where relevant, and GLP-grade work where the submission needs it.
  • Capacity and scale: match clinical-supply capability to commercial intent. A vendor that can build a few hundred devices for a Phase 1 study may not have the automated assembly and fill capacity to support launch. Ask about scale-up path, second-source strategy for critical device components, and lead times on tooling.
  • Regulatory experience: prefer teams that have actually supported a combination-product submission, can speak to PMOA and the request-for-designation process, and understand which center (CDER, CBER, or CDRH) is likely to lead. A clean FDA inspection history on both the drug and device sides matters more than the lowest bid.
  • IP and ownership: settle device design IP, tooling ownership, and the design history file in writing before work starts. With a platform device (a vendor's proprietary autoinjector, for instance) be precise about what you license versus what you own, and how you exit if you change partners.

Frequently asked questions

What is a combination product and why is it regulated differently?
A combination product pairs two or more regulated components: a drug plus a device (an autoinjector or prefilled syringe), a drug plus a biologic, or a device plus a biologic. The FDA assigns a primary mode of action (PMOA) that decides which center (CDER, CBER, or CDRH) leads the review, but the product still has to satisfy both the drug GMP and the device quality-system requirements. 21 CFR Part 4 is the rule that harmonizes those two sets of obligations so you are not running two disconnected programs. The practical consequence is that you carry CMC work and device design controls at the same time, and the agency reviews the assembled product as a single thing.
Do I need a separate device CRO and a fill-finish CDMO, or one vendor for both?
Both models work, and the right answer depends on your format and your internal bandwidth. Some specialist combination-product CDMOs run device design, human factors, fill-finish, and assembly under one roof, which removes the coordination tax and gives you a single owner of the design history file. Others are deep in one area only, so you pair a device-development house with an injectable fill-finish site and a human-factors CRO, then make them work to one integrated plan. If you split the work, someone has to own the seams (material compatibility, dose accuracy on the assembled product, the combined stability program), because that integration is where combination-product programs usually slip. On BioBridgeX you can source either way and contract once across all of them.
What is human factors testing and when do I need it?
Human factors (usability) engineering studies how real users handle your device, under IEC 62366 and the FDA's human-factors guidance. You run formative studies during development to find and fix use errors, then a summative validation study near design freeze to demonstrate that representative users can operate the device safely without critical errors. For a self-administered product (an autoinjector, a pen, an inhaler) this is a gating deliverable the FDA expects in the submission, not an optional extra. Plan for it early, because a validation study that surfaces a critical use error can send you back to a device design change, which is expensive late in the program.
What are extractables and leachables, and why do they matter for combination products?
Extractables are chemical species that can be pulled from the device materials (elastomers, plastics, adhesives, needle coatings) under aggressive lab conditions; leachables are what actually migrates into the drug under real storage and use. For a combination product the drug sits in prolonged contact with device materials, so an E&L study characterizes what could end up in the dose and whether it poses a toxicological risk. It pairs with container-closure integrity and material-compatibility work. This is core combination-product analytical work, and it is one of the studies that fails late if you do not start it once the device design and materials are reasonably locked.
What standards and quality systems apply to a combination product?
Several interlock. The drug or biologic side runs under pharmaceutical GMP (21 CFR Part 210/211 or the biologics equivalent). The device side runs under design controls (21 CFR 820.30) and typically an ISO 13485 quality management system. Biocompatibility of patient-contacting materials follows ISO 10993, and usability follows IEC 62366 plus FDA human-factors guidance. 21 CFR Part 4 ties the drug and device requirements together so one combined quality system covers the finished product. When you screen vendors, confirm they actually hold both the drug GMP and the device quality system, not just one.
Is sourcing combination product and device vendors on BioBridgeX free for buyers?
Yes. BioBridgeX is free for buyers and acts as a neutral vendor of record, so it has no lab or factory of its own and no reason to steer you toward a particular CDMO. Vendors pay a flat 2% fee. The structural advantage for a combination product is the contracting: instead of papering separate agreements with a device house, a fill-finish CDMO, and a human-factors CRO, you sign one contract, raise one purchase order, and receive one invoice across every vendor on the program. Coverage spans all indications and modalities, so the same account carries forward as your program moves from clinical supply into commercial manufacturing.

Source Combination Product / Device work with one contract

Compare transparent quotes from qualified Combination Product / Device CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes